Long term bromocriptine therapy in Cushing's disease

Recently, bromocriptine has been successfully introduced as medical therapy for the pituitary hypersecreting syndromes of hyperprolactinemia and acromegaly. Subsequently, an inhibitory effect on ACTH secretion was reported using bromocriptine in Cushing's disease. While most studies have focuse...

Full description

Saved in:
Bibliographic Details
Published inJournal of endocrinological investigation Vol. 5; no. 2; p. 117
Main Authors Kapcala, L P, Jackson, I M
Format Journal Article
LanguageEnglish
Published Italy 01.03.1982
Subjects
Adrenocorticotropic Hormone - blood
Adult
Bromocriptine - therapeutic use
Carbidopa
Cushing Syndrome - drug therapy
Humans
Hydrocortisone - urine
Levodopa
Male
Time Factors
Online AccessGet more information

Cover

More Information
Summary:Recently, bromocriptine has been successfully introduced as medical therapy for the pituitary hypersecreting syndromes of hyperprolactinemia and acromegaly. Subsequently, an inhibitory effect on ACTH secretion was reported using bromocriptine in Cushing's disease. While most studies have focused on the acute response to bromocriptine, few have investigated the response to chronic therapy with this agent. In this report, we describe a patient with Cushing's disease in whom an acute inhibition of ACTH and cortisol was demonstrated following bromocriptine and in whom the long term administration of bromocriptine as the sole therapy produced a transient beneficial response. Further pharmacologic testing suggested this inhibitory effect on the hypothalamic-pituitary-adrenal axis was mediated through dopaminergic stimulation.
ISSN:0391-4097
1720-8386
DOI:10.1007/bf03350502